Sustained Remission in Tumor Necrosis Factor Inhibitor-treated Patients with Rheumatoid Arthritis: A Population-based Cohort Study.
Einarsson, Jon Thorkell LU
; Geborek, Pierre
LU
; Saxne, Tore
LU
and C Kapetanovic, Meliha
LU
(2015)
In Journal of Rheumatology
42(5).
p.741-748
- Abstract
- To study frequency, possible baseline predictors, timing, and duration of sustained remission [SR; defined as 28-joint Disease Activity Score (DAS28) < 2.6 for at least 6 mos] in patients with established rheumatoid arthritis (RA) treated with different tumor necrosis factor (TNF) inhibitors [etanercept (ETN), infliximab (IFX), adalimumab (ADA)]. In addition, the aim was to compare (head-to-head) the effectiveness of individual drugs in patients receiving their first anti-TNF treatment.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/5143599
- author
- Einarsson, Jon Thorkell
LU
; Geborek, Pierre
LU
; Saxne, Tore
LU
and C Kapetanovic, Meliha
LU
- organization
- publishing date
- 2015
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Journal of Rheumatology
- volume
- 42
- issue
- 5
- pages
- 741 - 748
- publisher
- Journal of Rheumatology Publishing Company Limited
- external identifiers
-
- pmid:25684762
- wos:000353779400004
- scopus:84940546742
- pmid:25684762
- ISSN
- 0315-162X
- DOI
- 10.3899/jrheum.131502
- language
- English
- LU publication?
- yes
- id
- d4242dd4-15c9-4bc5-ab04-f99de6fdfb4d (old id 5143599)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/25684762?dopt=Abstract
- date added to LUP
- 2016-04-01 10:08:17
- date last changed
- 2022-02-02 06:45:22
@article{d4242dd4-15c9-4bc5-ab04-f99de6fdfb4d,
abstract = {{To study frequency, possible baseline predictors, timing, and duration of sustained remission [SR; defined as 28-joint Disease Activity Score (DAS28) < 2.6 for at least 6 mos] in patients with established rheumatoid arthritis (RA) treated with different tumor necrosis factor (TNF) inhibitors [etanercept (ETN), infliximab (IFX), adalimumab (ADA)]. In addition, the aim was to compare (head-to-head) the effectiveness of individual drugs in patients receiving their first anti-TNF treatment.}},
author = {{Einarsson, Jon Thorkell and Geborek, Pierre and Saxne, Tore and C Kapetanovic, Meliha}},
issn = {{0315-162X}},
language = {{eng}},
number = {{5}},
pages = {{741--748}},
publisher = {{Journal of Rheumatology Publishing Company Limited}},
series = {{Journal of Rheumatology}},
title = {{Sustained Remission in Tumor Necrosis Factor Inhibitor-treated Patients with Rheumatoid Arthritis: A Population-based Cohort Study.}},
url = {{http://dx.doi.org/10.3899/jrheum.131502}},
doi = {{10.3899/jrheum.131502}},
volume = {{42}},
year = {{2015}},
}